McCaskill Slams Insys’ Use of Speakers and Compensation Programs

Drug Industry Daily
A A
The latest opioid report from the office of Sen. Claire McCaskill (D-Mo.) delves into Insys Therapeutics’ sales policies for Subsys and concludes that the drugmaker used unethical methods to increase sales of its fentanyl product.

To View This Article:

Login

Subscribe To Drug Industry Daily